PDF(Pubmed)
Abstract：
OBJECTIVE: We conducted an updated systematic review and meta-analysis to investigate the effect of colchicine treatment on clinical outcomes in patients with COVID-19.
METHODS: Systematic review and meta-analysis.
METHODS: We searched PubMed, Embase, the Cochrane Library, medRxiv and ClinicalTrials.gov from inception to January 2023.
METHODS: All randomised controlled trials (RCTs) that investigated the efficacy of colchicine treatment in patients with COVID-19 as compared with placebo or standard of care were included. There were no language restrictions. Studies that used colchicine prophylactically were excluded.
METHODS: We extracted all information relating to the study characteristics, such as author names, location, study population, details of intervention and comparator groups, and our outcomes of interest. We conducted our meta-analysis by using RevMan V.5.4 with risk ratio (RR) and mean difference as the effect measures.
RESULTS: We included 23 RCTs (28 249 participants) in this systematic review. Colchicine did not decrease the risk of mortality (RR 0.99; 95% CI 0.93 to 1.05; I2=0%; 20 RCTs, 25 824 participants), with the results being consistent among both hospitalised and non-hospitalised patients. There were no significant differences between the colchicine and control groups in other relevant clinical outcomes, including the incidence of mechanical ventilation (RR 0.75; 95% CI 0.48 to 1.18; p=0.22; I2=40%; 8 RCTs, 13 262 participants), intensive care unit admission (RR 0.77; 95% CI 0.49 to 1.22; p=0.27; I2=0%; 6 RCTs, 961 participants) and hospital admission (RR 0.74; 95% CI 0.48 to 1.16; p=0.19; I2=70%; 3 RCTs, 8572 participants).
CONCLUSIONS: The results of this meta-analysis do not support the use of colchicine as a treatment for reducing the risk of mortality or improving other relevant clinical outcomes in patients with COVID-19. However, RCTs investigating early treatment with colchicine (within 5 days of symptom onset or in patients with early-stage disease) are needed to fully elucidate the potential benefits of colchicine in this patient population.
UNASSIGNED: CRD42022369850.
METHODS: Systematic review and meta-analysis.
METHODS: We searched PubMed, Embase, the Cochrane Library, medRxiv and ClinicalTrials.gov from inception to January 2023.
METHODS: All randomised controlled trials (RCTs) that investigated the efficacy of colchicine treatment in patients with COVID-19 as compared with placebo or standard of care were included. There were no language restrictions. Studies that used colchicine prophylactically were excluded.
METHODS: We extracted all information relating to the study characteristics, such as author names, location, study population, details of intervention and comparator groups, and our outcomes of interest. We conducted our meta-analysis by using RevMan V.5.4 with risk ratio (RR) and mean difference as the effect measures.
RESULTS: We included 23 RCTs (28 249 participants) in this systematic review. Colchicine did not decrease the risk of mortality (RR 0.99; 95% CI 0.93 to 1.05; I2=0%; 20 RCTs, 25 824 participants), with the results being consistent among both hospitalised and non-hospitalised patients. There were no significant differences between the colchicine and control groups in other relevant clinical outcomes, including the incidence of mechanical ventilation (RR 0.75; 95% CI 0.48 to 1.18; p=0.22; I2=40%; 8 RCTs, 13 262 participants), intensive care unit admission (RR 0.77; 95% CI 0.49 to 1.22; p=0.27; I2=0%; 6 RCTs, 961 participants) and hospital admission (RR 0.74; 95% CI 0.48 to 1.16; p=0.19; I2=70%; 3 RCTs, 8572 participants).
CONCLUSIONS: The results of this meta-analysis do not support the use of colchicine as a treatment for reducing the risk of mortality or improving other relevant clinical outcomes in patients with COVID-19. However, RCTs investigating early treatment with colchicine (within 5 days of symptom onset or in patients with early-stage disease) are needed to fully elucidate the potential benefits of colchicine in this patient population.
UNASSIGNED: CRD42022369850.
摘要：
目的：我们进行了最新的系统评价和荟萃分析，以研究秋水仙碱治疗对COVID-19患者临床结局的影响。
方法：系统评价和荟萃分析。
方法：我们搜索了PubMed，Embase,Cochrane图书馆,medRxiv和ClinicalTrials.gov从成立到2023年1月。
方法：包括所有随机对照试验（RCT），这些试验调查了秋水仙碱治疗COVID-19患者与安慰剂或标准治疗相比的疗效。没有语言限制。预防性使用秋水仙碱的研究被排除。
方法：我们提取了与研究特征相关的所有信息，比如作者姓名,location,研究人群,干预组和比较组的细节，以及我们感兴趣的结果。我们使用RevManV.5.4进行了荟萃分析，以风险比（RR）和平均差异为效果指标。
结果：在本系统评价中，我们纳入了23项RCT（28249名参与者）。秋水仙碱并未降低死亡风险(RR0.99;95%CI0.93~1.05;I2=0%;20项随机对照试验,25824名参与者)，结果在住院和非住院患者中一致。秋水仙碱组与对照组在其他相关临床结局方面无显著差异,包括机械通气的发生率(RR0.75;95%CI0.48至1.18;p=0.22;I2=40%;8项随机对照试验,13262名参与者)，重症监护病房入院(RR0.77；95%CI0.49至1.22；p=0.27；I2=0%；6项随机对照试验，961名参与者)和住院(RR0.74;95%CI0.48至1.16;p=0.19;I2=70%;3项随机对照试验，8572名参与者)。
结论：本荟萃分析的结果不支持使用秋水仙碱作为降低COVID-19患者死亡风险或改善其他相关临床结局的治疗方法。然而,需要研究秋水仙碱早期治疗（症状发作后5天内或在早期疾病患者中）的随机对照试验，以充分阐明秋水仙碱在该患者人群中的潜在益处。
■CRD42022369850。
方法：系统评价和荟萃分析。
方法：我们搜索了PubMed，Embase,Cochrane图书馆,medRxiv和ClinicalTrials.gov从成立到2023年1月。
方法：包括所有随机对照试验（RCT），这些试验调查了秋水仙碱治疗COVID-19患者与安慰剂或标准治疗相比的疗效。没有语言限制。预防性使用秋水仙碱的研究被排除。
方法：我们提取了与研究特征相关的所有信息，比如作者姓名,location,研究人群,干预组和比较组的细节，以及我们感兴趣的结果。我们使用RevManV.5.4进行了荟萃分析，以风险比（RR）和平均差异为效果指标。
结果：在本系统评价中，我们纳入了23项RCT（28249名参与者）。秋水仙碱并未降低死亡风险(RR0.99;95%CI0.93~1.05;I2=0%;20项随机对照试验,25824名参与者)，结果在住院和非住院患者中一致。秋水仙碱组与对照组在其他相关临床结局方面无显著差异,包括机械通气的发生率(RR0.75;95%CI0.48至1.18;p=0.22;I2=40%;8项随机对照试验,13262名参与者)，重症监护病房入院(RR0.77；95%CI0.49至1.22；p=0.27；I2=0%；6项随机对照试验，961名参与者)和住院(RR0.74;95%CI0.48至1.16;p=0.19;I2=70%;3项随机对照试验，8572名参与者)。
结论：本荟萃分析的结果不支持使用秋水仙碱作为降低COVID-19患者死亡风险或改善其他相关临床结局的治疗方法。然而,需要研究秋水仙碱早期治疗（症状发作后5天内或在早期疾病患者中）的随机对照试验，以充分阐明秋水仙碱在该患者人群中的潜在益处。
■CRD42022369850。
